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Objectives: Cystatin C (Cys C) and high-density lipoprotein (HDL) play critical roles
in neurodegenerative diseases, such as dementia, Alzheimer’s disease (AD) and
vascular dementia (VaD). However, whether they can be used as reliable biomarkers
to distinguish patients with dementia from healthy subjects and to determine disease
severity remain largely unknown.
Methods: We conducted a cross-sectional study to determine plasma Cys C and HDL
levels of 88 patients with dementia (43 AD patients, 45 VaD patients) and 45 healthy
age-matched controls. The severity of dementia was determined based on the Schwab
and England Activities of Daily Living (ADL) Scale, the Mini-mental State Examination
(MMSE), the Global Deterioration Scale (GDS), the Lawton Instrumental ADL (IADL)
Scale, and the Hachinski Ischemia Scale (Hachinski). Receiver operating characteristic
(ROC) curves were calculated to determine the diagnostic accuracy of Cys C and HDL
levels in distinguishing patients with dementia from healthy subjects.
Results: We found that plasma Cys C levels were higher, but HDL levels were lower
in AD and VaD patients respectively, compared to healthy control subjects. Yet, Cys C
levels were highest among patients with VaD. Interestingly, plasma Cys C levels were
significantly correlated with IADL Scale scores. In addition, the ROC curves for Cys C
Abbreviations: AD, Alzheimer’s disease; ADL, Schwab and England Activities of Daily Living Scale; AUC, area under the
curve; BUN, blood urea nitrogen; CNS, central nervous system; Cr, creatinine; Cys C, cystatin C; GDS, Global Deterioration
Scale; Hachinski, Hachinski Ischemia Scale; HDL, high-density lipoprotein; H&Y, modified Hoehn and Yahr Staging Scale;
IADL, Lawton Instrumental Activities of Daily Living Scale; MMSE, Mini-mental State Examination; NINCDS-ADRDA,
National Institute of Neurological and Communicative Diseases and Stroke-Alzheimer’s Disease and Related Disorders
Association; NINDS-AIREN, National Institute of Neurological Disorders and Stroke-Association Internationale pour la
Recherche et l’Enseignement en Neurosciences; ROC, receiver operating characteristic; rs, Spearman’s rank correlation
coefficient; rp, Pearson’s correlation coefficient; SD, standard deviation; UA, uric acid; VaD, vascular dementia.
Frontiers in Aging Neuroscience | www.frontiersin.org 1 February 2017 | Volume 9 | Article 26
Wang et al. Cys C and HDL as Biomarkers for AD and VaD
(area under the curve, AUC 0.816 for AD, AUC 0.841 for VaD) and HDL (AUC 0.800 for
AD, AUC 0.731 for VaD) exhibited potential diagnostic value in distinguishing AD/VaD
patients from healthy subjects. While the ROC curve for the combination of Cys C and
HDL (AUC 0.873 for AD, AUC 0.897 for VaD) showed higher diagnostic accuracy in
distinguishing AD/VaD patients from healthy subjects than the separate curves for each
parameter.
Conclusions: Our findings suggest that the inflammatory mediators Cys C and HDL
may play important roles in the pathogenesis of dementia, and plasma Cys C and HDL
levels may be useful screening tools for differentiating AD/VaD patients from healthy
subjects.
Keywords: Alzheimer’s disease, vascular dementia, cystatin C, high-density lipoprotein, dementia
Highlights
• Plasma Cys C levels were higher in patients with AD/VaD than
in healthy subjects.
• Plasma HDL levels were lower in patients with AD/VaD than
in healthy subjects.
• Plasma Cys C levels were significantly correlated with
dementia.
• The ROC curve for the combination of Cys C and HDL
showed potential diagnostic value in distinguishing AD/VaD
from healthy subjects.
INTRODUCTION
Dementia represents a broad category of brain diseases that
usually cause declines in memory and gradual decreases
in cognition that affect a person’s quality of life (Paulsen
et al., 2013). Common types of dementia include Alzheimer’s
disease (AD), vascular dementia (VaD), Lewy body dementia
(LBD), frontotemporal dementia (FTD), multiple system atrophy
dementia (MSA-D) and Parkinson’s disease dementia (PDD).
Among these, AD and VaD are the most common types (Posada-
Duque et al., 2014; Xu et al., 2014). AD is characterized by the
accumulation of amyloid-β (Aβ) peptides and Tau (Kandimalla
et al., 2011, 2014; Bourdenx et al., 2015; Hoppe et al., 2015).
Meanwhile, VaD is characterized by the occurrence of minor
strokes and the development of cognitive deficits (Ray et al.,
2013). However, it is hard to differentiate from each other only
based on the clinical features (Ray et al., 2013).
The cystatins (Cyss) are a family of cysteine protease
inhibitors. Cys B and C have been increasingly investigated in
neurological diseases such as AD and VaD. Cys B, a member
of the cysteine protease inhibitor family, plays an important
role in regulating abnormal accumulation of Aβ peptide and
maintaining lipofuscin-related autofluorescence and giant lipid-
containing autolysosomes in AD (Yang et al., 2011a,b, 2014;
Boyle et al., 2013). Cys C, a potent cysteine inhibitor that is
encoded by the Cys C (CST3) gene and that is secreted by
all human tissues, is found in all body fluids (Heywood et al.,
2015). It has been used as a biomarker of renal function as well
as a strong predictor of VaD and AD (Kaur and Levy, 2012;
Zhong et al., 2013). Multiple lines of evidence indicate that Cys
C is functionally associated with anti-inflammation (Dutta et al.,
2012; Jonsdottir et al., 2013) and exerts protective effects against
age-related diseases (Xu et al., 2005; Mi et al., 2007; Kaur et al.,
2010; Liu et al., 2014).
In AD and VaD, lipoproteins play crucial roles in preserving
cognitive function (Ray et al., 2013; Ahmed et al., 2014;
Dias et al., 2014). High-density lipoprotein (HDL) is part of
a heterogeneous group of lipoprotein particles that exist in
the systemic circulation and brain and mainly facilitate the
clearance and delivery of lipids and lipid-related molecules from
and throughout the body, respectively (Hottman et al., 2014).
Several lines of evidence suggest that plasma HDL and its main
protein component, apoA-I, also possess potent vasoprotective
properties such as facilitating improvements in vascular function,
inhibiting inflammation, suppressing endothelial reparation,
preventing lipid oxidation, and stimulating endothelial repair
(Stukas et al., 2014).
Both Cys C and HDL not only modulate dementia but also
associate with vascular function and mediate vasorelaxation,
inflammation, and oxidative stress (Dutta et al., 2012; Jonsdottir
et al., 2013; Stukas et al., 2014). Therefore, we are interested
in investigating the levels of Cys C and HDL in different types
of dementia. To our knowledge there is a paucity of studies
exploring the combined effects of Cys C and HDL in patients
with dementia. In this study, we investigate whether Cys C and
HDL are associated with the severity and prevalence of different
types of dementia. The primary aim of this study was to compare
plasma Cys C/HDL levels between patients with AD/VaD and
healthy subjects. The secondary aim of this study was to explore
the diagnostic value of plasma Cys C/HDL in dementia. Lastly,
we also aimed to determine the correlations between the above
plasma markers and the severity of dementia.
MATERIALS AND METHODS
Patients and Ethics Statement
This cross-sectional study was performed at the Department
of Neurology of the Third Affiliated Hospital Sun Yat-sen
University, Guangzhou, China. FromNovember 2012 to October
2015, a total of 88 patients with dementia (AD and VaD)
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were recruited for this study. Additionally, 43 patients with AD
(20 males and 23 females) were enrolled, and their diagnoses
were confirmed using the National Institute of Neurological and
Communicative Diseases and Stroke-AD and Related Disorders
Association (NINCDS-ADRDA) criteria for AD (McKhann
et al., 1984). This study also included 45 patients with VaD
(24males and 21 females) whose diagnoses were confirmed using
the National Institute of Neurological Disorders and Stroke-
Association Internationale pour la Recherche et l’Enseignement
en Neurosciences (NINDS-AIREN) criteria for VaD (Román
et al., 1993). The MMSE scores of all patients were less than
25. A total of 45 healthy age-matched subjects (16 males and
29 females) were recruited from the outpatient setting and served
as the control group. The control group was selected from the
Medical Examination Centre of the Third Affiliated Hospital
of Sun Yat-sen University. In this study, no subject presented
with hypertension, cardiopathy, diabetes or renal dysfunction. In
addition, none of the patients presented abnormal levels of the
prostate carcinoma-related mediators prostate-specific antigen
(PSA), carcinoembryonic antigen (CEA), and alpha-fetoprotein
(AFP).
This study was approved by the ethics committee of the
Third Affiliated Hospital of Sun Yat-sen University and was
conducted according to the principles outlined in the revised
Declaration of Helsinki of 1975 and the National Institutes of
Health Human Subjects Policies and Guidelines released in 1999.
All participants provided written consent to participate in the
investigation and allowed researchers to measure their plasma
Cys C and HDL levels. All subjects participated in the following
standardized assessments: the Schwab and England Activities
of Daily Living (ADL) Scale, the Webster Scale, the modified
Hoehn and Yahr Staging Scale (H&Y), the Mini-mental State
Examination (MMSE), the Global Deterioration Scale (GDS),
the Lawton Instrumental ADL (IADL) Scale, and the Hachinski
Ischemia Scale (Hachinski). Patients with different types of
disease participated in different standardized assessments, which
were all conducted in a blinded manner.
Study Design
Experienced neurologists were recruited to perform evaluations
and complete neurological examinations of both the inpatients
and the outpatients. All patients with AD met the NINCDS-
ADRDA criteria, and all patients with VaD met the NINDS-
AIREN criteria (Román et al., 1993). The following patients were
excluded: (1) patients with physical disability due to neurological
disorders other than AD or VaD such as congenital diseases or
psychosis; (2) patients with somatic disabilities caused by trauma
or other diseases that may affect ADL and IADL, including
pain syndromes, advanced diabetes mellitus, malignancy, renal
failure, hepatic failure, cardiopathy, severe anemia, or any other
acute or chronic debilitating or life-threatening disease/state;
(3) patients with MMSE scores higher than 25 (25 was included
in the study); and (4) patients who refused to participate in
the study. All subjects completed the following standardized
assessments: the ADL Scale, IADL Scale and GDS, which
stratified patients based on their clinical disabilities (Kaufman
et al., 2013); Hachinski, which stratified patients based on
whether they had VaD, AD or another type of dementia
(AD < 4, VaD > 7); and the MMSE, which evaluated
patient cognitive abilities. All scales were available and validated
for the Chinese population. All subjects have been scanned
by magnetic resonance imaging (MRI), and the typical MRI
for normal control, AD and VaD patients are shown in
Figure 1.
Blood Sample Measurements
Five milliliters of venous blood was taken to measure Cys C and
HDL levels. All measurements were repeated three times. Plasma
was isolated by centrifugation at 3000 rpm for 10 min within 1 h
of sample collection. The separated plasma was stored at −30◦C
FIGURE 1 | Magnetic resonance imaging (MRI) images in normal control, Alzheimer’s disease (AD) and vascular dementia (VaD) patients. (A) Healthy
control. (B) Cerebral atrophy and enlargement of the cerebral lateral ventricles of AD patients. (C) Leukoencephalopathy and encephalomalacia foci of VaD patients.
All MRI are shown in T2-weighted image.
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before laboratory evaluation (Chen et al., 2015; Gao et al., 2015).
Cys C levels were measured with a latex-enhanced reagent (N
Latex Cys C, Dade Behring, Deerfield, IL, USA), using a Behring
BN ProSpec Analyzer (Dade Behring). Plasma HDL levels were
measured via direct enzymatic methods, using commercial kits
(Cholestest N-HDL, Sekisui Medical, Tokyo, Japan) with less
than 3% intra-assay and inter-assay coefficients of variance.
Statistical Analysis
All continuous variables (age; MMSE, ADL, IADL, and GDS
scores; and HDL and Cys C levels) were presented as the
mean± standard deviation if the data were normally distributed
or as medians (min, max) if the data were not normally
distributed. Categorical variables are presented as percentages.
ADL and IADL scores were determined by summing individual
items. To assess the significance of differences between groups,
Student’s t test was applied when the data were normally
distributed. Tukey’s post hoc analysis was conducted to
compare differences in HDL and Cys C levels among normal
subjects, according to gender. Pearson’s correlation (rp) and
Spearman’s rank correlation (rs) coefficient were used to evaluate
correlations between different clinical parameters for normal
data and non-normal data, respectively. Receiver operating
characteristic (ROC) analysis was conducted to assess the
diagnostic value of specific clinical biomarkers (Cys C, HDL)
with respect to identifying the abovementioned diseases. In
addition, an ROC curve for the combination of Cys C and
HDL was calculated via logistic regression analysis to determine
the value of this combination in predicting disease progression.
p values < 0.05 were deemed statistically significant, and SPSS
13.0 software (Chicago, IL, USA) was used for the statistical
analyses.
RESULTS
Patient Characteristics
This cross-sectional study included 43 AD patients (20 males
[47%] and 23 [53%] females), 45 VaD patients (24 males [53%]
and 21 [47%] females), and 45 healthy subjects (16 males
[36%] and 29 females [64%]). The mean ages of the AD
patients, VaD patients and normal controls were 67.35 ± 10.48,
69.11± 7.98 and 64± 6.47 years, respectively. Clinical evaluating
parameters in AD and VaD were shown in Tables 1A. There
was no significance difference in age between the patients and
control subjects (AD vs. Control, p = 1.000; VaD vs. Control,
p = 0.191; Student’s t-test). The demographic and clinical data
for the subjects are shown in Tables 1A,B).
Comparisons of Cys C/HDL Levels
between Patients with Dementia and
Healthy Subjects
In this study, significant differences in plasma Cys C levels were
observed between patients with dementia (AD/VaD) and healthy
subjects (Table 2). Plasma Cys C levels were higher in AD and
VaD patients than in normal subjects (AD, 1.03 ± 1.94 vs.
0.83 ± 0.13, ∗∗p < 0.001; VaD, 1.07 ± 0.23 vs. 0.83 ± 0.13,
∗∗p< 0.001; Student’s t-test, (Tables 1A,B; Figure 2). Moreover,
in patients with AD or VaD, HDL levels were significantly lower
than in healthy subjects (AD: 1.15 ± 0.32 vs. 1.42 ± 0.25,
∗p = 0.023; VaD: 1.09 ± 0.32 vs. 1.42 ± 0.25, ∗∗p = 0.001,
Student’s t-test, Table 1B; Figure 2).
Correlations between Cys C and HDL
Levels and MMSE, ADL, IADL and GDS
Scores
We utilized correlation analysis to investigate the correlations
between the abovementioned inflammatory mediators and
various assessment tools. Depending on the data distribution,
Pearson’s and Spearman’s correlations were used separately for
different diseases to evaluate the correlations between disease
severity and clinical variables (Tables 3A,B). In AD patients,
there were significant correlations between Cys C levels and
Hachinski scores (rs = 0.349, ∗p = 0.022, Table 3A) and Cys C
levels and age (rs = 0.575, ∗∗p = 0.000, Table 3A). However, there
were no significant correlations between Cys C/HDL levels and
the scores of the other assessments. In VaD patients, a significant
correlation was noted only between HDL and age (rs = 0.403,
∗∗p = 0.006, Table 3B).
To eliminate the influence of confounders (e.g., gender), we
divided the AD and VaD patients and the healthy subjects into
two groups (females/males). In male AD patients, there were
significant correlations between Cys C levels and age (rs = 0.619,
∗∗p = 0.005, Table 3A) and Cys C levels and IADL scores
(rs = −0.464, ∗p = 0.046, Table 3A). Meanwhile, in female AD
patients, there were significant correlations between Cys C levels
and MMSE scores (rs = −0.413, ∗p = 0.045, Table 3A) Cys C
levels and Hachinski scores (rs = 0.524, ∗∗p = 0.009, Table 3A),
and Cys C levels and age (rs = 0.540, ∗∗p = 0.006, Table 3A).
However, in VaD patients, a significant correlation was observed
only between HDL and age (rs = 0.552, ∗∗p = 0.009, Table 3B).
ROC Analysis of the Utility of Cys C and
HDL Levels in the Diagnosis of Dementia
ROC analysis was conducted to determine the diagnostic value
of Cys C and HDL, according to the area under the ROC curve
(AUC). Using ROC analysis, we determined the capacity of
the above markers to distinguish patients with dementia from
normal subjects. We also analyzed Cys C and HDL levels in AD
patients. The AUC for Cys C was 0.816 (95% CI: 0.724–0.908,
∗∗∗p < 0.001); the cut-off was 0.91 µmol/L, with a sensitivity of
79% and a specificity of 78%. Similarly, the AUC for HDL was
0.731 µmol/L (95% CI: 0.759–0.923, ∗∗∗p < 0.001); the cut-off
was 1.04 µmol/L, with a sensitivity of 42% and a specificity
of 98%. Furthermore, in VaD patients, the AUC for Cys C
was 0.841 (95% CI: 0.627–0.835, ∗∗∗p < 0.001); the cut-off was
at 0.97 µmol/L, with a sensitivity of 81% and a specificity of
51%. The AUC for Cys C was 0.800 (95% CI: 0.705–0.894,
∗∗∗p < 0.001); the cut-off was 1.14 µmol/L, with a sensitivity of
64% and a specificity of 89% (Figure 3).
In addition, we also conducted an ROC analysis for the
combination of Cys C and HDL in different types of dementia.
The AUC for AD was 0.873 (95% CI: 0.797–0.950, ∗∗∗p< 0.001),
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TABLE 1A | Clinical parameters in Alzheimer’s disease (AD).
Variable AD AD M AD F
Mean (SD) Min Max Mean (SD) Min Max Mean (SD) Min Max
MMSE 14.00 0 22 14.00 0 22 12.50 0 21
ADL (Barthel) 95.00 20 100 90.00 20 100 95.00 55 100
GDS 5.00 3 7 5.00 3 7 5.00 3 6
Hachinski 2.00 1 3 2.00 1 3 2.00 1 3
IADL 5.00 0 17 5.00 0 15 9.00 0 17
Abbreviations: MMSE, Mini-mental State Examination; ADL, Schwab and England Activities of Daily Living Scale; GDS, Global Deterioration Scale; Hachinski, Hachinski
Ischemia Scale; IADL, Lawton Activities of Daily Living Scale.
TABLE 1B | Clinical parameters in vascular dementia (VaD).
Variable VaD VaD M VaD F
Mean (SD) Min Max Mean (SD) Min Max Mean (SD) Min Max
MMSE 16.10 (5.18) 3 24 15.29 (5.20) 3 23 17.19 (5.10) 6 24
ADL (Barthel) 82.50 20 100 87.50 20 100 75.00 20 100
GDS 4.00 2 6 4.00 3 5 4.00 2 6
Hachinski 11.00 7 14 9.50 7 14 11.00 7 13
IADL 13.13 (3.50) 6 21 13.13 (3.44) 6 21 13.38 (3.65) 4 19
Abbreviations: MMSE, Mini-mental State Examination; ADL, Schwab and England Activities of Daily Living Scale; GDS, Global Deterioration Scale; Hachinski, Hachinski
Ischemia Scale; IADL, Lawton Activities of Daily Living Scale.
with a sensitivity of 91% and a specificity of 73%, and the cut-off
was 0.36, depending on the predicted risk algorithm. Meanwhile,
the AUC for VaD was 0.897 (95% CI: 0.831–0.964, ∗∗∗p< 0.001);
the cut-off was 0.34, depending on the predicted risk algorithm,
with a sensitivity of 91% and a specificity of 78%. These data
suggest that the ROC curve for the combination of AD/VaD has
a higher diagnostic value than the separate curves for uric acid
(UA) or HDL alone in distinguishing AD and VaD patients from
healthy subjects.
DISCUSSION
In the present study, we explored variations in plasma Cys C
and HDL levels in AD and VaD and noted several interesting
results. First, we observed a remarkable increase in plasma Cys
C levels and a decrease in HDL levels in AD/VaD patients
compared to healthy subjects. Second, we noted significant
correlations between plasma Cys C levels and severity scores in
AD and VaD patients. Third, ROC analysis strongly suggested
that the combination of Cys C and HDL can significantly
distinguish AD and VaD patients from healthy subjects and can
therefore be used as a new screening and diagnostic instrument.
The AUC increased after incorporating plasma Cys C and
HDL levels. This means that the diagnostic accuracy of the
combination of the two variables was superior to that of either
variable alone in differentiating AD/VaD patients from healthy
subjects. To our knowledge, this is the first study to explore
variations in plasma Cys C and HDL levels in AD and VaD
patients.
AD and VaD are neurodegenerative diseases with different
etiologies and pathogeneses. Therefore, it is important to
explore the underlying mechanisms of these diseases and the
usefulness of specific biomarkers in evaluating their severity
and progression. There is evidence that inflammatory responses
may be associated with the pathogenesis of AD and VaD, and
there are also some clinical similarities between AD and VaD as
both diseases cause gradual impairments in cognition, follow a
progressive course, and affect activities of daily living. Several
lines of recent evidence show that both Cys C and HDL can
act as anti-inflammatory mediators and exert neuroprotective
effects against AD and VaD progression (Gauthier et al., 2011;
Hottman et al., 2014; Stukas et al., 2014). However, whether
Cys C and HDL can be used in the evaluation and diagnosis
of AD and VaD remains unknown. Therefore, we examined
TABLE 2 | Comparison of Cystatin C (Cys C), high-density lipoprotein (HDL), CREAT, blood urea nitrogen (BUN) and uric acid (UA) levels among AD
patients, VaD patients and normal healthy subjects.
Variable Control AD VaD p value p value
Mean ± SD Mean ± SD Mean ± SD Control vs. AD Control vs. VaD
CYSC 0.83 ± 0.13 1.03 ± 1.94 1.07 ± 0.23 < 0.001∗∗ < 0.001∗∗
HDL 1.42 ± 0.25 1.15 ± 0.32 1.09 ± 0.32 0.023∗ 0.001∗∗
CREAT 69.00 ± 12.89 75.67 ± 13.76 77.41 ± 17.94 0.558 0.257
BUN 5.51 ± 1.33 5.57 ± 1.61 5.62 ± 1.92 1.000 1.000
UA 316.64 ± 59.28 345.43 ± 91.07 323.31 ± 93.84 0.772 1.000
Age 64 ± 6.47 67.35 ± 10.48 69.11 ± 7.98 1.000 0.191
∗p < 0.05, ∗∗p < 0.01. Student’s t test.
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FIGURE 2 | Comparison of Cystatin C (Cys C) and high-density lipoprotein (HDL) levels between AD/VaD patients and control subjects.
(A) Comparison of Cys C levels between the dementia and control groups. ∗∗AD vs. control, p < 0.001; ∗∗VaD vs. control, p < 0.001. (B) Comparison of Cys C
levels between the dementia and control groups according to gender. ∗AD (male) vs. control (male), p = 0.035; ∗∗AD (female) vs. control (female), p = 0.014; ∗∗VaD
(male) vs. control (male), p = 0.043; ∗∗VaD (female) vs. control (female), p < 0.001. (C) Comparison of HDL levels between the dementia and control groups. ∗AD vs.
control, p = 0.023; ∗∗VaD vs. control, p = 0.001. (D) Comparison of HDL levels between the dementia and control groups according to gender. No significant
differences in HDL levels were found between the dementia (male) and control (male) and dementia (female) and control (female) groups.
TABLE 3A | Spearman’s rank correlation coefficient (rs) and p values pertaining to the relationships between clinical variables and MMSE, IADL, GDS,
Hachinski and ADL scores in AD.
Variable AD (total) AD (male) AD (female)
CYSC HDL-C CYSC HDL-C CYSC HDL-C
r p r p r p r p r p r p
MMSE 0.069 0.658 0.110 0.479 −0.278 0.250 0.220 0.365 0.413∗ 0.045 0.041 0.851
IADL −0.065 0.681 0.176 0.258 −0.464∗ 0.046 0.151 0.536 0.335 0.110 −0.033 0.877
GDS 0.036 0.820 −0.197 0.204 0.447 0.055 −0.216 0.375 −0.310 0.140 −0.193 0.366
Hachinski 0.349∗ 0.022 −0.002 0.989 0.060 0.806 −0.106 0.667 0.524∗∗ 0.009 0.034 0.875
ADL (Barthel) −0.081 0.602 0.188 0.222 −0.368 0.121 0.098 0.689 0.157 0.463 0.142 0.507
Age 0.575∗∗ 0.000 0.042 0.788 0.619∗∗ 0.005 −0.015 0.952 0.540∗∗ 0.006 0.152 0.479
∗p < 0.05, ∗∗p < 0.01. Abbreviations: r, Spearman’s rank correlation coefficient; MMSE, Mini-mental State Examination; ADL, Schwab and England Activities of Daily
Living Scale; GDS, Global Deterioration Scale; Hachinski, Hachinski Ischemia Scale; IADL, Lawton Activities of Daily Living Scale.
whether these anti-inflammatory mediators can be employed
as viable and reliable biomarkers in diagnosing AD and VaD
and in assessing their severities. We also identified clinical
variables that are associated with AD andVaD in different gender
groups.
Although the present, Cys C’s function in the brain is unclear,
but it has been implicated in both neuronal degeneration and
nervous system repair. Enhanced CysC expression occurs in
human patients and in animal models of neurodegenerative
conditions (Liu et al., 2014). In our study, we noted significantly
increased plasma Cys C levels in AD and VaD patients compared
to healthy subjects. These results were consistent with previous
reports. Similar results were observed in two previous cross-
sectional studies that noted higher and lower plasma Cys C
levels in AD andMCImild cognitive impairment (MCI) patients,
respectively, and an increasing but non-significant trend in these
levels in AD patients compared to those in healthy subjects
(Ghidoni et al., 2010; Sundelöf et al., 2010). This finding implies
that plasma Cys C may play an important role in AD and VaD.
However, different studies have reported lower CSF levels of Cys
C in AD patients and no significant changes in plasma Cys C
levels in AD patients compared to controls (Hansson et al., 2009;
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TABLE 3B | Pearson and Spearman’s rank correlation coefficient (rs) and p values pertaining to the relationship between clinical variables and MMSE,
IADL, GDS, Hachinski and ADL scores in VaD.
Variable VaD (total) VaD (male) VaD (female)
CYSC HDL-C CYSC HDL-C CYSC HDL-C
r p r p r p r p r p r p
MMSE 0.036 0.816 0.150 0.326 −0.132 0.538 0.085 0.694 0.121 0.601 0.147 0.525
IADL −0.028 0.854 0.045 0.781 0.014 0.948 0.195 0.361 −0.042 0.858 −0.246 0.282
GDS −0.003 0.986 0.166 0.277 0.082 0.704 0.168 0.433 −0.010 0.967 0.199 0.388
Hachinski 0.121 0.430 −0.074 0.631 0.071 0.742 −0.133 0.537 0.216 0.348 −0.116 0.617
ADL (Barthel) 0.054 0.724 −0.016 0.919 0.149 0.487 0.236 0.267 −0.022 0.926 −0.178 0.440
Age 0.128 0.401 0.403∗∗ 0.006 −0.014 0.949 0.195 0.361 0.317 0.161 0.552∗∗ 0.009
∗p < 0.05, ∗∗p < 0.01. Abbreviations: MMSE and IADL scale scores were analyzed via Pearson’s correlation; GDS, ADL scale scores and Hachinski scores were analyzed
by Spearman’s rank correlation; MMSE, Mini-mental State Examination; ADL, Schwab and England Activities of Daily Living Scale; GDS, Global Deterioration Scale;
Hachinski, Hachinski Ischemia Scale; IADL, Lawton Instrumental Activities of Daily Living Scale.
FIGURE 3 | Receiver operating characteristic (ROC) curves evaluating the utility of plasma levels of Cys C and HDL in distinguishing patients with
dementia from healthy controls. (A) The area under the curves (AUCs) of the ROC curves for Cys C in AD and VaD were 0.816 (95% CI: 0.724–0.908,
∗∗∗p < 0.001) and 0.841 (95% CI: 0.627–0.835, ∗∗∗p < 0.001). (B) The AUCs of the ROC curves for HDL in AD and VaD were 0.731 (95% CI: 0.759–0.923,
∗∗∗p < 0.001) and 0.800 (95% CI: 0.705–0.894, ∗∗∗p < 0.001). (C) The AUCs of the ROC curves for Cys C + HDL in AD and VaD were 0.873 (95% CI:
0.797–0.950, ∗∗∗p < 0.001) and 0.897 (95% CI: 0.831–0.964, ∗∗∗p < 0.001).
Zhong et al., 2013). Sundelöf et al. (2008) also indicated that low
levels of plasma Cys C precede clinical AD in elderly men who
are free of dementia at baseline and may be an indicator of future
AD risk. We speculate that during the early stages of diseases
such as MCI, Cys C fails to protect neurons from the toxicity of
oligomeric Aβ, which contributes to AD (Kaur and Levy, 2012),
while during the later stages of dementia, Cys C levels increase in
response to disease progression to protect neurons from further
damage. Differences in study design and a lack of correlation
between CSF Cys C and plasma Cys C levels or GFR may explain
the differences in the results of studies regarding Cys C and AD
risk. Prospective studies regarding Cys C levels in CSF in relation
to future AD risk are lacking. Thus, longitudinal studies of Cys
C levels in CSF in relation to AD risk are needed (Sundelöf et al.,
2010).
Low levels of HDL were associated with an increased risk for
neuronal degeneration (Ward et al., 2010; Liu et al., 2014; Cai
et al., 2016; Zhang et al., 2016). We noted decreased plasma HDL
levels in AD and VaD patients compared to healthy subjects,
implying that HDL contributes to the pathophysiological
mechanisms underlying these disease processes. HDL-mediated
anti-oxidative stress processes play an important role in
the pathogenesis of AD and VaD. The precise mechanisms
underlying the involvement of HDL in AD and VaD have not yet
been elucidated, but we theorize that decreases in plasma HDL
may exert vasoprotective effects, preserve cognitive function, and
weaken anti-inflammatory responses in AD and VaD patients
(Patterson and Holahan, 2012; Hottman et al., 2014; Stukas et al.,
2014). Cys C and HDL are strongly correlated with vascular
function (Kaur and Levy, 2012; Dias et al., 2014; Hottman et al.,
2014; Villeneuve et al., 2014). Here, we observed that the plasma
levels of Cys C and HDL were higher and lower, respectively,
in VaD than in AD, respectively. This strongly suggests that
vascular remodeling plays a more important role in VaD than
in AD (Kaur and Levy, 2012; Dias et al., 2014; Villeneuve et al.,
2014).
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Numerous lines of evidence indicate that Cys C and HDL
are associated with cognitive diseases (Kaur and Levy, 2012). In
this study, we observed correlations between Cys C levels and
Hachinski scores and age via Pearson’s correlation analysis. After
dividing the subjects according to gender, we observed a positive
correlation between IADL/MMSE sores and plasma Cys C levels
in female AD patients. These results strongly imply that plasma
Cys C levels can be used to assess cognitive dysfunction and
quality of life in patients with dementia.
Because multiple lines of evidence support the
neuroprotective roles of Cys C and HDL in neurodegenerative
disorders and cognitive decline (Ghidoni et al., 2011; Hottman
et al., 2014), we aimed to determine whether the combination
of Cys C and HDL levels can be applied to distinguish AD
and VaD patients from healthy subjects and to evaluate disease
progression. To determine the diagnostic value of plasma Cys
C and HDL in AD and VaD, we conducted an ROC analysis
and noted an AUC of 0.816 for Cys C and an AUC of 0.731 for
HDL in AD and an AUC of 0.841 for Cys C and an AUC of
0.80 for HDL in VaD. The AUCs for Cys C and HDL were
all higher than 0.70 in AD and VaD, which means that both
Cys C and HDL have high diagnostic value and an acceptable
sensitivity and specificity for distinguishing AD/VaD patients
from healthy subjects. Notably, Cys C and HDL were more
reliable in distinguishing patients from healthy subjects in
VaD than in AD (Figures 3A,B). Moreover, the combination
of Cys C and HDL exhibited a better ability to distinguish
between patients and controls than Cys C or HDL alone, with
an AUC of 0.873 for AD and an AUC of 0.897 for VaD. The
reliability and potential utility of the combination of Cys C
and HDL as a diagnostic plasma biomarker in screening for
AD and VaD is r eflected in our ROC analysis. Our findings
have important clinical relevance. Using plasma Cys C and
HDL levels as a screening tool, clinicians may be able to
detect AD and VaD and screen for early disease in AD/VaD
patients.
There were several limitations to our study that should
not be ignored: (1) a small number of participants (43 AD
patients, 45 VaD patients and 45 normal subjects) were recruited;
(2) genetic factors, such as the CST3 and APOA1–2 genotypes,
and anti-lipemic administration were not considered in this
study; and (3) to validate and complete the questionnaire, we
chose only AD and VaD patients with sufficient cognitive ability,
which significantly narrowed the study population. The above
limitations may have resulted in bias with respect to Cys C and
HDL levels in AD and VaD patients. Therefore, it is necessary to
conduct larger population studies in the future.
In summary, the findings of the current study support the
idea that inflammation and vascular burden may contribute
to the pathogenesis of AD and VaD. Of the biomarkers
studied (Creatinine (Cr), blood urea nitrogen (BUN), UA,
Cys C and HDL), Cys C and HDL were the most suitable
and reliable anti-inflammatory mediators in distinguishing AD
and VaD patients from healthy subjects and in evaluating
disease progression. We speculate that higher Cys C levels and
lower HDL levels may be associated with an elevated risk of
dementia and may predispose patients to progressive disease.
The anti-inflammatory effects of Cys C and HDL are important
as they provide testable parameters that are related to the
pathophysiology of AD and VaD. ROC curves, in combination
with plasma Cys C and HDL levels, may be valuable for
early diagnosis of AD and VaD and may be used to increase
diagnostic accuracy with respect to differentiating AD and VaD
patients from healthy subjects. Our findings support the use
of plasma Cys C and HDL levels to diagnose AD and VaD,
but neuropathological correlations may be required to confirm
the diagnoses. To our knowledge, this is the first study to
consider the combination of plasma Cys C and HDL levels in
diagnosing and assessing the severity of AD and VaD. Additional
studies are needed to determine whether plasma Cys C and HDL
abnormalities are reliable parameters in distinguishing patients
with dementia from healthy subjects, particularly during the early
stages of disease.
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